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Poster Session II 125There is no effective therapy for patients(pts) who develop SR-
GVHD following allogeneic hematopoietic cell transplanta-
tion(HCT). Cytokines such as IL2 & TNFa have been identified
as mediators of acute GVHD.However, single agent antibody ther-
apy against the IL2 receptor(daclizumab) or TNFa (infliximab) has
only modest activity in SR-GVHD.We hypothesized that concom-
itant blockade of both TNFa& IL2 would be more effective in this
condition than inhibitionof either cytokine alone. Between 2/02 and
10/07, 131 pts with solid tumors(n 5 69), hematologic malignan-
cies(n5 15) or nonmalignant hematologic diseases(n5 47) under-
went nonmyeloablative HCT from a 6/6(n 5 128) or 5/6(n 5 3)
HLA-matched family donor at our institution. Pre-transplant con-
ditioning consisted of cyclophosphamide & fludarabine given alo-
ne(n 5 89) or with ATG(n 5 42). Cyclosporine, plus either
MMF(n 5 45) or MTX(n 5 86) was used as GVHD prophylaxis.
Twenty one pts developed grade 3–4 SR-GVHD(GVHD that did
not improve after$6 days of$1 mg/kg methylprednisolone [MP],
including $3 days of high dose MP) a median of 28 days following
HCT; involved organs included the lower GI tract(n 5 21), liver
(n 5 3) & skin (n 5 7). All pts received daclizumab (1 mg/kg,
days1,4,8,15,22) & infliximab (10 mg/kg, days1,8,15,22). Measures
to minimize the risk of opportunistic infections were rigorously ap-
plied & included aspergillus prophylaxis, empiric broad-spectrum
antibiotics, surveillance blood cultures & a rapid reduction in the
dose of MP (#1 mg/kg). We observed a remarkably high response
rate following therapy, with 19/21(90%) pts experiencing complete
resolution(CR) of GVHD in affected organs. Responses were usu-
ally delayed(median onset 2 weeks) but durable, with all responders
recovering sufficiently for hospital discharge. The most notable
complication associated with therapy was the development of inva-
sive fungal infections in three pts; in two of these, prophylactic anti-
fungal therapy had been prematurely discontinued due to drug
toxicity.Nine patients are alive at the time of this analysis, with ame-
dian survival of 255 days (range 37–1724 d). Four pts died from pro-
gression of their underlying solid tumor, two from complications
related to CMV, & four from complications related to GVHD (in-
cluding three from invasive fungal infections). These data suggest
combined TNFa/IL2 blockade is an effective therapeutic option
for pts with SR-GVHD& highlight the need for aggressive antimi-
crobial prophylaxis in the management of this condition.340
RESPONSE TO STEROIDS AS PRIMARY THERAPY FOR ACUTE GRAFT-
VERSUS-HOST DISEASE (GVHD) IN 280 HEMATOPOIETIC STEM CELL
TRANSPLANT (HSCT) RECIPIENTS: COMPARISON OF UNRELATED DO-
NOR (URD) BONE MARROW (BM) AND UMBILICAL CORD BLOOD (UCB)
MacMillan, M.L., Wagner, J.E., Arora, M., DeFor, T.E., Blazar, B.R.,
Weisdorf, D.J. University of Minnesota, Minneapolis, MN.
Acute GVHD remains a major cause of morbidity and mortality
after allogeneic HSCT. To date, there has been no comparison of
URD HSC sources in terms of response to primary therapy for
acute GVHD. Therefore, we evaluated the response in 280 patients
with grade II-IV acute GVHD, treated with prednisone 60 mg/m2
as initial therapy between 1995–2006 at the University of Minne-
sota. One hundred and thirty-one patients received URD donor
BM, and 149 receivedURDUCB.UCB recipients were more likely
to be: transplanted more recently, have greater HLA disparate
grafts, treated with non-myeloablative conditioning, and receive
CSA/MMF as GVHD prophylaxis. The groups had similar recipi-
ent age, gender, maximum initial acute GVHD grade, and days
from HSCT to acute GVHD. The day 28 response was defined
as the maximum acute GVHD grade (and organ stage) at 28 days
(614 days) of prednisone therapy. Complete response (CR) was de-
fined as resolution of acute GVHD in all organs maintained for 28
days (to day 56) without additional treatment. Partial response (PR)
was defined as improvement of GVHD in all organs without CR
and without worsening in any organ. CR and overall response
(OR5CR1PR) occurred in 102 (36%) and 167 (60%), respectively.
Adjusting for differences between groups, factors favorably associ-
ated with achieving CR included use of non-myeloablative condi-
tioning (RR 2.1 vs 1.0 for myeloablative conditioning [95% CI,
1.2–3.6, p 5 .03]), onset of acute GVHD later than day 130 (RR
3.4 vs 1.0 for earlier onset [95% CI, 1.9–5.8, p\ .01]), grade II-III GVHD (RR 21.4 vs 1.0 for grade IV GVHD [95% CI, 2.8–
165.2, p\ .01]) and single organGVHD (RR 2.1 vs 1.0 for multiple
organ GVHD [95% CI, 1.2–3.6, p\ .01]). These factors were also
associated with OR. Probability of survival at 6 months after initia-
tion of steroid therapy was 64% (95%CI 59–69%) for the entire co-
hort. In Cox regression, factors associated with lower 6 month
mortality were use of UCB (RR 0.6 vs 1.0 for BM [95% CI, 0.4–
0.9, p 5 .02]), and grade II-III acute GVHD (RR of death 0.4 vs
1.0 for grade IV [95% CI, 0.3–0.7, p\ .01]). While mortality was
less in recipients of UCB, more effective GVHD therapy is needed
for patients with multiple organ involvement and for those with
grade IV acute GVHD regardless of HSC source.341
ALLOGENEIC ANTIBODIES SPECIFICALLY TARGET AML ANTIGEN NU-
SAP1 AFTER BONE MARROW TRANSPLANTATION
Wadia, P.P., Coram, M., Butte, A., Miklos, D.B. Stanford University,
Stanford, CA.
Allo-antibody (allo-ab) responses that develop after an allogeneic
hematopoietic cell transplant (HCT) in sex-mismatch transplant
patients are associated with cGVHD, persist even after 2 years
post-transplant and are quantitative.We hypothesize that novel mi-
nor histocompatibility antigens (mHA) can be serologically identi-
fied as targets of allo-ab responses that develop after an allogeneic
HCT. For this study, plasma was collected from five AML patients
one year post-transplant, pre-transplant, and from their donors and
detected against 5,000 full-length human proteins with N-terminal
GST epitopes presented on V3.0 ProtoArrayTM (Invitrogen). Tar-
gets of allo-Ab were identified after subtracting the pre-transplant
fluorescent signal intensities from their one-year plasma results
and then characterized for donor plasma response. New allo-Ab re-
sponses targeted 60–75 antigens with fluorescent differences rang-
ing 0.5 to 3 logs.
Two of the five patients showed Nucleolar and Spindle Associ-
ated Protein 1 (NuSAP1) and Chromatin Assembly Factor 1b
(CHAF1b) as the two predominant proteins recognized after
HCT. Exon DNA sequencing has failed to identify SNPs encoding
disparate amino acid polymorphisms. However gene expression
profiles showed NuSAP1 was up-regulated in AML as compared
to other types of leukemia. Therefore we hypothesize the allo-ab
immune response targets NuSAP1 due to increased expression as
a tumor associated antigen. We directly confirmed using RT-
PCR that NuSAP1 expression was the highest in AML peripheral
blood lymphocytes (Table attached) as compared to all other cell
populations sorted from GM-CSF mobilized peripheral blood
from healthy donors. To identify if antibodies specifically recog-
nized and targeted the potential tumor antigenNuSAP1 post-trans-
plant, 87 patients were screened by ELISA for allo-ab responses
against NuSAP1. Allo-ab against NuSAP1 were significantly higher
in patients post-transplant with AML (n5 27) as compared to ALL,
CLL, CML, MCL, MM and NHL, with a significance of p 5
0.0011 for NuSAP1 using Wilcox test.
NuSAP1 and CHAF1b were also highly expressed on
CD341Thy11 stem cells from healthy donors by RT-PCR.
ELISA results demonstrated that patients post-transplant also de-
veloped allo-ab responses to CHAF1b though these responses
were not significantly associated with disease. Taken together this
data suggests that allo-ab target tumor antigens and molecules
highly expressed in the hematopoietic stem cells.Relative mRNA expression
when normalized to ActinCell Populations NuSAP1 CHAF1bPatient AML PBSC (n 5 5) 17.06827 0.27725
Cell Populations from
healthy donors
CD341/THY11 (n 5 4) 9.297199 0.621888
CD3 (n 5 7) 2.243828 0.201833
CD19 (n 5 5) 2.030201 0.371341
PBSC (n 5 11) 2.950317 0.086726
